Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance
On Oct. 7, 2026, researchers at Fred Hutch Cancer Center announced they have identified a previously overlooked molecular…
-
-
Biotechnology | FDA | Oncology
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
On Jul. 31, 2026, Novartis announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177…
-
Researchers discover new form of hereditary prostate cancer
On July 9, 2026, researchers at the University of British Columbia announced they have identified a new form of hereditary…
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05 billion, revolutionize treatment of cancer
On Nov. 17, 2025, Johnson & Johnson announced that it has entered into a definitive agreement to acquire…
-
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection
On Oct. 18, 2025, GRAIL announced that positive performance and safety results from its registrational PATHFINDER 2 study…
-
Biotechnology | Disease | Genomics | Oncology
Revolutionary blood test for ME / Chronic Fatigue unveiled
On Oct. 8, 2025, scientists at the University of East Anglia and Oxford Biodynamics announced they have developed a…
-
Study uncovers key role of RNA modifications in prostate cancer progression
On Mar. 24, 2025, scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto…
-
Combination approach showed promise for treating rare, aggressive cancers
On Nov. 12, 2024, a research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that…
-
Biotechnology | Disease | Life Science History | NIH | Oncology | Radiology | Therapeutics | Women's Health
American Association for Cancer Research released biennial Cancer Disparities Progress Report 2024
On May 15, 2024, the American Association for Cancer Research (AACR) released its biennial Cancer Disparities Progress Report…
-
Biotechnology | Clinical Research | COVID-19 | FDA | HIV | Infectious Disease | Oncology | Therapeutics
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
-
FDA approved first oral hormone therapy for teating advanced prostate cancer
On Dec. 18, 2020, tthe U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult…
-
FDA approved first PSMA-targeted PET imaging drug for men with prostate cancer
On Dec. 1, 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) ﾖ the first drug for…
-
Biotechnology | Diagnostics | NIH | Oncology | Therapeutics
Testing with combined biopsy method improves prostate cancer diagnosis in NCI study
On Mar. 4, 2020, a method of testing for prostate cancer developed at the National Cancer Institute (NCI)…
-
Biotechnology | Diagnostics | NIH | Oncology | Therapeutics
Karmanos Cancer Institute and the University of Michigan Rogel Cancer Center received a $9.2 million grant from the National Cancer Institute
On Sept. 23, 2019, the Barbara Ann Karmanos Cancer Institute and the University of Michigan Rogel Cancer Center…
-
Canadian Cancer Trials Group announced IND.234 clinical trial using liquid biopsy technology for prostrate cancer screening
On Nov. 27, 2018, the Canadian Cancer Trials Group, a new clinical trial, opened across Canada. This was…
-
Keck School of Medicine announced $26.5 million grant to fund firstﾠ large-scale study on African-American men with prostate cancer
On Jul. 17, 2018, the Keck School of Medicine of USC announced that it was leading a $26.5…
-
FDA authorized direct-to-consumer test that reports three mutations in the BRCA breast cancer genes
On Mar. 6, 2018, the U.S. Food and Drug Administration (FDA) authorized 23andMe’s Personal Genome Service Genetic Health…
-
Omahan Donated $3 million for prostate cancer research to Buffett Cancer Center
On Dec. 13, 2017, longtime Omaha art teacher and businessman Gerald “Jerry” Pabst donated $3 million through an…
-
New prostate cancer therapy investigated at Vanderbilt University Medical Center
On Sept. 22, 2016, Vanderbilt University Medical Center became the world’s first site to treat a prostate cancer…
-
Korff estate gifted $5 million to advance prostate cancer research and treatments in Nebraska
On Nov. 12, 2015, a major philanthropic donation was announced from longtime supporters, Ruth and Bill Scott, will…
-
Rutgers Cancer Institute of New Jersey was one of seven worldwide sites to offer debulking prostatectomy
On May 5, 2015, Rutgers Cancer Institute of New Jersey was one of seven international sites to offer…
-
Single antibody shrinks variety of human tumors transplanted into mice, study showed
On Mar. 26, 2012, researchers at Stanford University School of Medicine reported study results that showed human tumors…
-
Biotechnology | FDA | Oncology | Therapeutics
PROVENGE was approved by the FDA
On Apr. 29, 2010, the FDA approved sipuleucel-T (PROVENGE), made by the Dendreon, an autologous cellular immunotherapy for…
-
The largest-ever prostate cancer prevention study showed that Selenium and Vitamin E do not help prevent prostate cancer
On Dec. 9, 2008, in contrast with earlier research suggesting that dietary supplementation with selenium and vitamin E…
-
Biotechnology | Diagnostics | Disease | Genomics | Life Science History | NIH | Oncology
National Cancer Institute researchers discovered common variation in a gene segment that increases risk for prostate cancer
On Apr. 1, 2007, National Cancer Institute (NCI) researchers report that a set of genetic variations in at…
-
The National Cancer Institute released preliminary data on genetic susceptibility for prostate cancer
On Oct. 19, 2006, the National Cancer Institute part of the National Institutes of Health, announced it had…
-
National Cancer Institute launched a cancer biorepository pilot project to standardize biospecimen collection
On Nov. 7, 2005, the National Cancer Institute launched a cancer biorepository pilot project designed to standardize biospecimen…
-
Death rates from the lung, breast, prostate, and colorectal cancers continued to decline in the late 1990s
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
-
Results of the Prostate Cancer Prevention Trial were announced
On Jun. 24, 2003, results of the Prostate Cancer Prevention Trial (PCPT), testing the effectiveness of finasteride to…
-
The Winship Cancer Institute received a $10 million award from the U.S. Dept of Defense for prostate cancer research
On Mar. 24, 2003, the Winship Cancer Institute at Emory University announced it had received a $10 million…
